Theratechnologies Inc. (THTX)
Company Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.
The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Country | Canada |
Founded | 1993 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 103 |
CEO | Paul Lévesque |
Contact Details
Address: 2015 Peel Street, 5th Floor Montreal, A8 H3A 1T8 Quebec, Canada | |
Phone | 514-336-7800 |
Website | theratech.com |
Stock Details
Ticker Symbol | THTX |
Exchange | NASDAQ |
Fiscal Year | December - November |
Reporting Currency | USD |
CIK Code | 0001512717 |
CUSIP Number | 88338H100 |
ISIN Number | CA88338H7040 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Paul Lévesque | President, Chief Executive Officer and Director |
Philippe Dubuc M.B.A., MBA | Senior Vice President and Chief Financial Officer |
Jocelyn Lafond L.L.M., LL.B. | General Counsel and Corporate Secretary |
Dr. Christian Marsolais Ph.D. | Senior Vice President and Chief Medical Officer |
John Leasure | Global Commercial Officer |
Hon. Andre Dupras M.Sc. | Vice President of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 22, 2024 | 6-K | Report of foreign issuer |
Mar 22, 2024 | 6-K | Report of foreign issuer |
Mar 21, 2024 | 6-K | Report of foreign issuer |
Feb 29, 2024 | 6-K | Report of foreign issuer |
Feb 27, 2024 | 6-K | Report of foreign issuer |
Feb 21, 2024 | 20-F | Annual and transition report of foreign private issuers |
Feb 21, 2024 | 6-K | Report of foreign issuer |
Feb 15, 2024 | 6-K | Report of foreign issuer |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |